Andera Partners

Andera Partners Co-Leads $196 Million Round for Kestra Medical and Welcomes Raymond W. Cohen to Board of Directors

Andera Partners’ Portfoliounternehmen JenaValve von Edwards Lifesciences übernommen

Andera Partners Portfoliounternehmen TRiCares sammelt 50 Mio. USD in Serie D-Finanzierung ein

Andera Partners’ portfolio company Amolyt Pharma completes acquisition by AstraZeneca

Andera Partners führt gemeinsam mit einem Konsortium eine 63 Mio. € Serie A-Finanzierung für das Münchner Autoimmun-Biotechunternehmen SciRhom an

Andera Partners‘ Portfoliounternehmen Tubulis schließt überzeichnete Serie B2-Finanzierungsrunde in Höhe von 128 Mio. € ab, um die Entwicklung seiner ADC-Pipeline zu beschleunigen

Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca

Andera Partners führt überzeichnete 67,5 Mio. € Serie-C-Finanzierung für das Krebsimmuntherapie-Unternehmen Nouscom an

Andera Partners co-leads a €40 million Series A of Dualyx, a Belgian biotech developing novel Treg therapies for autoimmune diseases

Andera Partners ernennt Stefan Keitel zum Senior Advisor für die DACH-Region und stärkt damit seine Präsenz auf dem deutschen, österreichischen und schweizerischen Private Equity-Markt

Andera Partners co-leads a Series A extension round totalling € 47.75 million for radiopharmaceutical company Ariceum Therapeutics

Andera Partners leads $48.5 Million Series A financing for medical device company BioVentrix®

Andera Partners co-leads $25m extension round for FIRE1, an Irish medtech developing breakthrough technology for patients with heart failure

Ahead of its business plan, Andera Partners approaches 4 billion euros in assets under management and announces a new 2028 target of 6 to 8 billion euros

Andera Partners Portfolio Company Mineralys Therapeutics Successfully Completes Upsized $192 Million Nasdaq IPO

Andera Partners Participates in the €45 Million Series B Financing of Grey Wolf Therapeutics, led by Pfizer Ventures, to Advance First-of-its-Kind Neoantigen Creation Approaches

Andera Partners invests in SoniVie, a medtech company developing a promising device for the treatment of hypertension

Andera Partners participates in the $138 Million Series C Financing of Amolyt Pharma led by Sofinnova Partners and co-led by Intermediate Capital Group

Andera Partners erhält 456 Millionen Euro für seinen bisher größten Life Sciences Fonds und bestätigt so die Attraktivität des Sektors und seines Impacts

Andera Partners strengthens its Life Sciences team with a new partner

Andera Partners co-leads $118 Million Oversubscribed Series B Financing of Mineralys Therapeutics to Advance the Development of Novel, Targeted Treatment for Hypertension

Andera Partners supports Tubulis in a €60 million Series B financing to accelerate the development of its ADCs

Andera Partners veräußert Beteiligung an Life Science-Portfoliounternehmen ReViral an Pfizer

Andera Partners supports TargED Biopharmaceuticals in €39 million Series A financing to bring groundbreaking thrombolytic treatment to patients

Andera Partners’ Portfolio Company T-knife Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies

Andera Partners stärkt seine Präsenz in der DACH-Region